Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV

NCT06589167 | Not Yet Recruiting

• 1 other identifier: Metabolic syndrome and NAFLD
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.investigate the Prevalence of combined hepatic steatosis in patients with chronic HBV.
2. 2.to evaluate clinical characteristics of chronic HBV patients combined with metabolic syndrome and hepatic steatosis

Conditions

Metabolic Syndrome; Fatty Liver Disease

Keywords

Metabolic syndrome; Nonalcoholic fatty liver disease; hepatic steatosis

Outcome Measures

Primary Outcomes (1)

• investigate the Prevalence of combined hepatic steatosis in patients with chronic HBV

  baseline

Secondary Outcomes (1)

• evaluate clinical characteristics of chronic HBV patients combined with metabolic syndrome and hepatic steatosis

  baseline

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

total coverage of all patients with HBV aged 18-60 years,not combined with HCV or HIV.

You may qualify if:

• Age above 18 years.

You may not qualify if:

• Age below 18 years.
• Patients with combined HBV,HCV,HIV.
• Patients refused to contribute in this study.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (13)

• Mohammed H, Eshetie A, Melese D. Prevalence of hepatitis B virus and associated risk factors among adults patients at Dessie referral and Kemise general hospitals in northeastern Ethiopia. Health Sci Rep. 2022 May 22;5(3):e659. doi: 10.1002/hsr2.659. eCollection 2022 May.

  PMID: 35620544 BACKGROUND

• Bhat M, Ghali P, Deschenes M, Wong P. Prevention and Management of Chronic Hepatitis B. Int J Prev Med. 2014 Dec;5(Suppl 3):S200-7.

  PMID: 26622990 BACKGROUND

• National Clinical Guideline Centre (UK). Hepatitis B (Chronic): Diagnosis and Management of Chronic Hepatitis B in Children, Young People and Adults. London: National Institute for Health and Care Excellence (UK); 2013 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK254250/

  PMID: 25473721 BACKGROUND

• Swarup S, Ahmed I, Grigorova Y, Zeltser R. Metabolic Syndrome. 2024 Mar 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK459248/

  PMID: 29083742 BACKGROUND

• Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic Syndrome Pathophysiology and Predisposing Factors. Int J Sports Med. 2021 Mar;42(3):199-214. doi: 10.1055/a-1263-0898. Epub 2020 Oct 19.

  PMID: 33075830 BACKGROUND

• Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23. doi: 10.1016/j.ecl.2013.09.009.

  PMID: 24582089 BACKGROUND

• Aboulghate M, Elaghoury A, Elebrashy I, Elkafrawy N, Elshishiney G, Abul-Magd E, Bassiouny E, Toaima D, Elezbawy B, Fasseeh A, Abaza S, Voko Z. The Burden of Obesity in Egypt. Front Public Health. 2021 Aug 27;9:718978. doi: 10.3389/fpubh.2021.718978. eCollection 2021.

  PMID: 34513789 BACKGROUND

• Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14.

  PMID: 36517002 BACKGROUND

• Tourkochristou E, Assimakopoulos SF, Thomopoulos K, Marangos M, Triantos C. NAFLD and HBV interplay - related mechanisms underlying liver disease progression. Front Immunol. 2022 Dec 5;13:965548. doi: 10.3389/fimmu.2022.965548. eCollection 2022.

  PMID: 36544761 BACKGROUND

• Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. Clin Mol Hepatol. 2023 Apr;29(2):320-331. doi: 10.3350/cmh.2022.0422. Epub 2023 Feb 1.

  PMID: 36726053 BACKGROUND

• Dai YN, Xu CF, Pan HY, Chen MJ, Yu CH. Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection. BMC Infect Dis. 2023 Sep 28;23(1):637. doi: 10.1186/s12879-023-08632-y.

  PMID: 37770837 BACKGROUND

• Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, Han NX, Fong KY, Chen E, Wong C, Rui F, Xu X, Xue Q, Hu XY, Leow WQ, Goh GB, Cheung R, Wong G, Wong VW, Yu MW, Nguyen MH. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023 Jul;29(3):705-720. doi: 10.3350/cmh.2023.0004. Epub 2023 May 8.

  PMID: 37157776 BACKGROUND

• Liu L, Li H, Zhang Y, Zhang J, Cao Z. Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis. Heliyon. 2023 Jan 20;9(1):e13113. doi: 10.1016/j.heliyon.2023.e13113. eCollection 2023 Jan.

  PMID: 36747946 BACKGROUND

MeSH Terms

Conditions

Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Fatty Liver

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Liver Diseases; Digestive System Diseases

Study Officials

• Hadeer Abd El-Sattar

  Assiut University

  PRINCIPAL INVESTIGATOR

• Ghadaa Abdel rahman

  Assiut University

  STUDY DIRECTOR

• Bahaa Osman Taha

  Assiut University

  STUDY DIRECTOR

Central Study Contacts

Hadeer A Abd El-Sattar

CONTACT

01025454235; mohammedhadeer101@gmail.com

Ghada A Abdel rahman

CONTACT

01004301177; ghadaa1980@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor

Study Record Dates

• First Submitted: August 9, 2024
• First Posted: September 19, 2024
• Study Start: September 7, 2024
• Primary Completion: September 7, 2025
• Study Completion: October 1, 2025
• Last Updated: September 19, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share